We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 11-20 of 1,132

The Trans-Pacific partnership: changes for patents and pharmaceuticals?
  • Gowling Lafleur Henderson LLP
  • Asia-Pacific, Canada
  • October 8 2015

Changes may be on the horizon for Canada’s legal and regulatory regime for patents and pharmaceuticals. Included in the Trans-Pacific Partnership

Pharma in brief - Apotex Inc. and Apotex Pharmachem Inc. are ordered to disgorge profits in excess of $61 million
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 10 2015

Apotex Inc. (Apotex) and Apotex Pharmachem Inc. (Pharmachem) have been ordered by the Federal Court to pay to Adir and Servier Canada

Federal Court holds compound patent to cinacalcet to be anticipated and obvious
  • Osler Hoskin & Harcourt LLP
  • Canada
  • November 11 2015

The Federal Court released its reasons in Amgen Canada Inc v Mylan Pharmaceuticals ULC on November 3, 2015.The Court dismissed an application

Gilead has successfully obtained a declaration of invalidity of a patent that it reasonably expected would be asserted against it
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2015

The Federal Court has allowed Gilead’s claim to invalidate Idenix's '191 patent on the grounds of insufficient disclosure and lack of demonstrated

Patent utility update in Canada clarity may not be explicitly promised
  • SIM. IP Practice
  • Canada
  • June 4 2015

In the past five years, the Canadian Federal Court has invalidated several patents based on an arguably “technical” deficiency the

An example in a prior art patent inevitably anticipated the invention, even if it was not stated
  • Borden Ladner Gervais LLP
  • Canada
  • September 9 2015

In an NOC proceeding, Mylan has successfully alleged invalidity of Takeda's patent claiming the compound pantoprazole magnesium dihydrate. Mylan made

Pharma in brief - Generic v. Generic PM(NOC) application dismissed for non-infringement
  • Norton Rose Fulbright Canada LLP
  • Canada
  • April 21 2015

In a recently published Public Judgment and Reasons, Justice Gleason dismissed Teva Canada Innovation and Teva Pharmaceutical

Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a

Federal Court upholds validity of patent for escitalopram (CIPRALEX)
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 19 2013

Apotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is

Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian